Repurposing Belinostat for Alleviation of Atopic Dermatitis

Area of Science:

• Dermatology and immunology
• Epigenetics and non-coding RNA research

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition with significant impact on quality of life.
• Pathophysiology involves immune responses and skin barrier defects, with mechanisms not fully elucidated.
• miR-335, a microRNA, is crucial for keratinocyte differentiation and skin barrier integrity.

Discussion:

• miR-335 expression is reduced in AD, contributing to skin barrier dysfunction.
• Histone deacetylase inhibitors, such as belinostat, show potential in restoring miR-335 levels.
• Belinostat effectively resolved skin barrier defects in a dry skin model.

Key Insights:

• Loss of miR-335 is a key factor in AD-related skin barrier defects.
• Belinostat demonstrates therapeutic potential by restoring miR-335 and skin barrier function.
• The study highlights the interplay between epigenetic regulation and non-coding RNAs in AD.

Outlook:

• Further research is needed on the crosstalk between epigenetic and non-coding RNA regulation in AD.
• Exploring epigenome-targeting therapeutic strategies for AD is a promising avenue.
• Investigating belinostat's efficacy and safety in clinical AD settings is warranted.